KR870002844A - 약제학적 조성물의 제조방법 - Google Patents

약제학적 조성물의 제조방법 Download PDF

Info

Publication number
KR870002844A
KR870002844A KR1019860007498A KR860007498A KR870002844A KR 870002844 A KR870002844 A KR 870002844A KR 1019860007498 A KR1019860007498 A KR 1019860007498A KR 860007498 A KR860007498 A KR 860007498A KR 870002844 A KR870002844 A KR 870002844A
Authority
KR
South Korea
Prior art keywords
converting enzyme
angiotensin converting
physiologically acceptable
enzyme inhibitor
loop diuretic
Prior art date
Application number
KR1019860007498A
Other languages
English (en)
Other versions
KR940010032B1 (ko
Inventor
벡커 라인하르트
가이거 롤프
헤닝 라이너
테쯔 폴커
우르바흐 한스외르그
Original Assignee
베른하르트 벡크, 하인리히 벡케
훽스트 아크티엔 게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6280420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR870002844(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 베른하르트 벡크, 하인리히 벡케, 훽스트 아크티엔 게젤샤프트 filed Critical 베른하르트 벡크, 하인리히 벡케
Publication of KR870002844A publication Critical patent/KR870002844A/ko
Application granted granted Critical
Publication of KR940010032B1 publication Critical patent/KR940010032B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Toys (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음

Description

약제학적 조성물의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제 1도는 시간에 대한 초기혈압(MBP0)의 %로서 평균혈압(MPPt)의 변화를 나타낸다.

Claims (10)

  1. a) 안지오텐신 전환효소 억제제 또는 이의 염 및 b) 루프이뇨제 또는 이의 염을 생리학적으로 허용 가능한 부형제 및 경우에 따라 다른 보조제 또는 첨가제와 함께 적합한 투여형태로 전환시킴을 특징으로하여, a)안지오텐신 전환효소 억제제 또는 이의 생리학적으로 허용되는 염 및 b) 루프이뇨제 및 이의 생리학적으로 허용되는 염을 함유하는 약제학적 조성물을 제조하는 방법.
  2. 제 1항에 있어서, 루프이뇨제 또는 이의 염의 아(sub)-이뇨 투여량이 참가된 방법.
  3. 제 1항 또는 제 2항에 있어서, 제조된 조성물이 일반식(I)의 루프이뇨제를 함유하는 방법.
    상기 식에서,
    R1은 염소 또는 페녹시를 나타내고,
    R2는 수소, 피롤리디노 또는 m-부틸아미노를 나타내며,
    R3는 수소 또는 2-푸릴메틸아미노를 나타낸다.
  4. 제 1 내지 3항중 어느 한 항에 있어서, 제조된 조성물이 구조식(Ⅱ) 또는 (Ⅱ')의 루프이뇨제를 함유하는 방법.
  5. 제 1내지 4항중 어느 한 항에 있어서, 제조된 조성물이 일반식(Ⅲ)의 안지오텐신 전환효소 억제제를 함유하거나 일반식(Ⅳ)의 안지오텐신 전환효소 억제제를 함유하는 방법.
    상기 식에서,
    R은 수소, 메틸, 에틸 또는 벤질을 나타내며,
    R4는 수소 (C1-C4)-알킬 또는 벤질을 나타낸다.
  6. 제 1 내지 5항중 어느 한 항에 있어서, 제조된 조성물이 R 또는 R4가 에틸을 나타내는 일반식(Ⅲ) 또는 (Ⅳ)의 안지오텐신 전환효소 억제제 또는 이의 생리학적으로 허용되는 염을 함유하는 방법.
  7. a)안지오텐신 전환효소 억제제 또는 이의 생리학적으로 허용되는 염 및 b) 루프이뇨제 또는 이의 생리학적으로 허용되는 염을 생리학적으로 허용가능한 부형제 및 경우에 따라, 다른 보조제 및 첨가제와 함께 적합한 투여형태로 전환시킴을 특징으로 하여, 고혈압의 치료를 위하여 동시투여, 분복투여 또는 연속투여를 위한 혼합생성물로서, 상기 (a) 및 (b)성분을 함유하는 생성물을 제조하는 방법.
  8. 제 7항에 있어서, 루프이뇨제 또는 이의 염이 아-이뇨 투여량으로 첨가된 방법.
  9. 제 8항 또는 9항에 있어서, 제 3항 내지 6항중 어느 한 항에서 정의된 바와같은 성분을 사용하여 수행되는 방법.
  10. 안지오텐신 전환효소 억제제를 일반식(I)의 루프이뇨제와 반응시킴을 특징으로 하여, a)안지오텐신 전환효소 억제제 및 b) R1,R2및 R3가 제 3항에서 정의된 바와같은 일반식(I)의 루프이뇨제로 부터 염을 제조하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860007498A 1985-09-09 1986-09-08 고혈압 치료용 약제학적 조성물의 제조방법 KR940010032B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19853532036 DE3532036A1 (de) 1985-09-09 1985-09-09 Pharmazeutische zubereitung zur behandlung des bluthochdrucks
DEP3532036.2 1985-09-09

Publications (2)

Publication Number Publication Date
KR870002844A true KR870002844A (ko) 1987-04-13
KR940010032B1 KR940010032B1 (ko) 1994-10-21

Family

ID=6280420

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860007498A KR940010032B1 (ko) 1985-09-09 1986-09-08 고혈압 치료용 약제학적 조성물의 제조방법

Country Status (19)

Country Link
EP (1) EP0215357B1 (ko)
JP (1) JPH089549B2 (ko)
KR (1) KR940010032B1 (ko)
AT (1) ATE75610T1 (ko)
AU (1) AU597270B2 (ko)
CA (1) CA1340722C (ko)
DE (2) DE3532036A1 (ko)
DK (1) DK166755B1 (ko)
ES (1) ES2001940A6 (ko)
FI (1) FI863594A (ko)
GR (1) GR862285B (ko)
HU (1) HU200685B (ko)
IE (1) IE59308B1 (ko)
IL (1) IL79965A (ko)
NO (1) NO863583L (ko)
NZ (1) NZ217489A (ko)
PH (1) PH23716A (ko)
PT (1) PT83322B (ko)
ZA (1) ZA866810B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1337400C (en) * 1987-06-08 1995-10-24 Norma G. Delaney Inhibitors of neutral endopeptidase
DK9200258U4 (da) * 1992-03-11 1993-07-23 Merck & Co Inc Farmaceutisk præparat indeholdende enalapril til brug mod hypertension
WO2001080895A2 (en) * 2000-04-26 2001-11-01 First Horizon Pharmaceutical Corporation Methods and compositions for the treatment of cardiac indications
WO2005067887A2 (en) * 2004-03-24 2005-07-28 Actavis Group Formulations of ramipril
DK3173075T3 (en) 2015-11-27 2019-01-21 Accupharma Spolka Z Ograniczona Odpowiedzialnoscia PHARMACEUTICAL COMBINATION PREPARATION OF ACE INHIBITOR AND LOOPDIURETIC

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4283407A (en) * 1977-09-28 1981-08-11 Science Union Et Cie Thiopropionamides, and the pharmaceutical compositions
US4217347A (en) * 1977-12-27 1980-08-12 E. R. Squibb & Sons, Inc. Method of treating hypertension and medicaments therefor
CA1120400A (en) * 1977-12-27 1982-03-23 Zola P. Horovitz Method of treating hypertension and medicaments therefor
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
FR2419728A1 (fr) * 1979-01-05 1979-10-12 Science Union & Cie Nouvelles compositions pharmaceutiques a action hypotensive et procede pour les preparer
US4482725A (en) * 1980-04-03 1984-11-13 E. R. Squibb & Sons, Inc. S-Acylation products of mercaptoacyl amino acids and carboxyl group containing diuretics
JPS56145220A (en) * 1980-04-10 1981-11-11 Dainippon Pharmaceut Co Ltd Antihypertensive agent containing prolylamino acid derivative and diuretic agent as main constituent

Also Published As

Publication number Publication date
FI863594A (fi) 1987-03-10
EP0215357A2 (de) 1987-03-25
ATE75610T1 (de) 1992-05-15
PT83322B (pt) 1989-05-12
DE3685177D1 (de) 1992-06-11
NO863583D0 (no) 1986-09-08
HU200685B (en) 1990-08-28
DE3532036A1 (de) 1987-03-26
IE59308B1 (en) 1994-02-09
JPS6261928A (ja) 1987-03-18
PT83322A (pt) 1986-10-01
NZ217489A (en) 1990-07-26
NO863583L (no) 1987-03-10
DK427886A (da) 1987-03-10
DK166755B1 (da) 1993-07-12
ZA866810B (en) 1987-04-29
JPH089549B2 (ja) 1996-01-31
ES2001940A6 (es) 1988-07-01
AU597270B2 (en) 1990-05-31
FI863594A0 (fi) 1986-09-05
PH23716A (en) 1989-09-27
KR940010032B1 (ko) 1994-10-21
AU6243186A (en) 1987-03-12
CA1340722C (en) 1999-09-07
DK427886D0 (da) 1986-09-08
HUT41640A (en) 1987-05-28
DE3685177T (ko) 1992-06-11
EP0215357B1 (de) 1992-05-06
IL79965A0 (en) 1986-12-31
EP0215357A3 (en) 1989-07-26
GR862285B (en) 1987-01-12
IE862392L (en) 1987-03-09
IL79965A (en) 1990-08-31

Similar Documents

Publication Publication Date Title
EP0221041A3 (en) Benzimidazole derivatives, process for their preparation and their pharmaceutical use
NO166448C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolidindioner.
SE8300623D0 (sv) Farmaceutisk komposition innehallande stabil mikrokristallin cis-platina(ii)-diammindiklorid (cisplatin)
DK275488A (da) Indolonderivater
KR930002330A (ko) 아미노-치환된 피페라진 유도체
LV10954A (lv) Benzimidazola atvasinajumi to iegusanas panemiens un tos saturosa farmaceitiska kompozicija
EP0173664A3 (en) Biologically active benzimidazole compounds and process for their preparation
DE68906609T2 (de) Dopamin-vorlaeufer.
KR970025615A (ko) 암 전이 억제제
RU96109699A (ru) Гуанидиды алкенилкарбоновых кислот, способ их получения, содержащее их лекарственное или диагностическое средство, способ его получения, способ лечения и профилактики сердечных заболеваний
ES8505379A1 (es) Un metodo de fabricar 1, 4-dihidropiridina-3-carboxilatos
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
KR870002844A (ko) 약제학적 조성물의 제조방법
HUT57204A (en) Process for producing 4-fluoro-2-///4-methoxy-2-pyridinyl/-methyl/-sulfinyl/-1h-benzimidazol with gastric acid secration-diminishing activity and pharmaceutical compositions containing them
US5739159A (en) Medicaments for the treatment of cardiac insufficiency
NO169487C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2,3-dihydrobenzofuran-5-sulfonamider
BE902796A (fr) Ester d'acetyl carnitine, sa preparation et son utilisation.
SE8704436D0 (sv) Anvendning av antisekretoriska substanser for nya indikationer
ATE40987T1 (de) Acetylenische phenoxypropanolderivate und pharmazeutische zusammensetzungen fuer die behandlung von bluthochdruck.
FR2362849A1 (fr) Nouvelles heterocyclo-omega-pentanorprostaglandines aryliques substituees en position 2 et medicament les contenant
KR880004810A (ko) 소화성 궤양 치료제
HU9500175D0 (en) Pharmacologically active alpha-[tertiary-aminomethyl]-benzenemethanol derivatives
EP0218953A3 (en) Derivatives of 19,20-bis-nor-prostanoic acid with antiulcer and anorectic activity, process for their preparation and pharmaceutical compositions thereof
KR830009776A (ko) 세포 보호 유도방법
KR880009943A (ko) 피리다지논 유도체

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20050729

Year of fee payment: 12

EXPY Expiration of term